Early Phase 1 Peripheral Arterial Disease Trial, Recruiting NCT07260656 Sponsor: Carilion Clinic Condition: Peripheral Arterial Disease
Back to Peripheral Arterial Disease

Early Phase 1 Peripheral Arterial Disease Trial, Recruiting

NCT07260656
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have at least 3 toes on each foot
  • People whose feet are otherwise in generally intact condition
  • People who do not have skin conditions such as eczema, thickened skin, hardened skin disorders, or excessive sweating on the areas of the foot where the study product would be applied
  • People who agree to apply the study product to painful areas of the feet as directed by research staff
  • People who agree to apply the study product to their feet twice per day as instructed
  • People who agree to wait 60 minutes after each application before completing pain rating forms
  • People who agree to wait at least 60 minutes before washing their feet after applying the study product, unless a burning sensation occurs shortly after application
  • People who are willing to use the study product without knowing which specific version they have been given

Who may not be able to join:

  • People younger than 25 or older than 75 years of age
  • People with any skin condition that could affect the skin's surface or change sensation in the feet
  • People who have had open wounds, skin sores, infections, skin irritation (such as poison oak), eczema, injury, or burns (including sunburn) on the feet within the past 30 days
  • People who have recently had surgery involving the feet
  • People who are currently using topical products on their feet — including herbal, cannabinoid, medicated patches, pain relief creams or gels, anti-inflammatory products, or steroid products — unless those products have been used consistently and regularly before the study began
  • People who currently misuse substances
  • People with a known allergy or sensitivity to chili peppers, coconut oil, shea butter, or sunflower seed oil
  • People who are receiving other foot pain treatments at the same time, such as massage, electrophoresis, or red light therapy (note: mobility-related therapies such as physical therapy or exercise may be acceptable — confirm with trial site)
  • People who are currently enrolled in another clinical trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Robert Carpenter, MD, Carilion Clinic

Phone: (540) 240-1695

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Carilion Clinic
Registry
ClinicalTrials.gov
Start date
26 November 2025
Est. completion
1 November 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Significant reduction in foot pain in participants with chronic diabetic neuropathic foot pain.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov